IL2 and neoplasm: After in vitro expansion via anti-CD3-mediated T cell activation in the presence of high doses of IL-2 and reinfusion in tumor-bearing mice, these TILs demonstrated a 50- to 100-fold higher therapeutic potency compared with lymphocyte cultures that were not derived from the tumor [32].